INTRODUCTION
Hypertension, an important risk factor for cardiovascular diseases (CVDs), affected an estimated one billion people worldwide in 2000 [1, 2] . This number is expected to rise to 1.56 billion by 2025 [1] . In China, hypertension is the leading preventable risk factor for premature mortality [3] . The majority of cardiovascular (CV) deaths in China were attributed to hypertension (2.11 million) in 2005 [3] . The China National Nutrition and Health Survey findings indicated that nearly 0.2 billion (18%) adults in 2002 had hypertension and only 6.1% of them achieved blood pressure (BP) control [4] . In 2010, a survey conducted among Chinese adults aged C18 years revealed that the prevalence of hypertension was 33.5% [5] .
According to the Chinese guidelines (2010) for the management of hypertension, a reduction in systolic BP (SBP) and diastolic BP (DBP) less than 140/90 mmHg in all hypertensive patients, and less than 130/80 mmHg in patients with concomitant diabetes or chronic kidney disease (CKD) is essential to reduce the risk of CV mortality [6] . However, evidence from a previous study suggests that only a small proportion of the hypertensive population in China receives adequate treatment or achieves effective BP control [7] . Single-drug therapy or monotherapy is the preferred way to initiate hypertension treatment, but BP goals (\140/90 mmHg)
cannot always be achieved with single-drug therapy in patients who require strong BP reductions [8, 9] . It has been proposed that in high-risk hypertensive patients who require a rapid and pronounced BP control, single-pill combination (SPC) or fixed-dose combination can be beneficial as a first-line therapy [10] . SPCs offer several advantages such as improved efficacy, reduced adverse events (AEs), and improved patient compliance compared with monotherapy [8] . Safe and effective combination of two or more drug classes is recommended for the majority of patients with hypertension to achieve their BP goal, which may translate into reduced risk of CV outcomes [8] [9] [10] [11] [12] [13] [14] . The 2013 European Society of Hypertension/European Society of Cardiology Guidelines for the management of arterial hypertension recommend the initiation of hypertension treatment with a combination of two drugs from different classes in patients with stage 2 hypertension (SBP C160 mmHg or DBP C100 mmHg) [15] . Moreover, use of an antihypertensive drug combination in a single pill may further enhance BP control by reducing pill burden and enhancing compliance [8, 16] .
Amlodipine (Aml) and valsartan (Val) are widely used antihypertensive drugs that have also been established to improve CV/renal outcomes [17, 18] . 
METHODS

Study Design
This was a multicenter, post-marketing, prospective observational study enrolled adult patients with essential hypertension, whose BP was not adequately controlled by monotherapy.
Patients from 238 regional centers across 29 provinces of China were enrolled from October blockers, CCBs, and diuretics).
Safety Assessments
Safety assessments included recording and measurement of all AEs and vital signs in the safety population. The incidence of AEs was recorded at week 4 and 8 of the study period. Each AE was defined by its duration, severity, and relationship to the study drug.
Statistical Analysis
Full analysis set (FAS) included patients with at least one post-baseline efficacy evaluation, and safety set (SS) included patients with at least one post-baseline safety evaluation. The FAS was used for all efficacy analyses. All statistical analyses were performed using SAS Ò Software version 9.2 (SAS Institute Inc., Cary, NC, USA) at two-sided significance level (P) of \0.05. 
RESULTS
Demographic and Baseline Characteristics
A total of 11,422 patients were enrolled for the study, of which 27 patients were excluded for violating GCP, 71 patients did not meet the inclusion criteria, and 63 patients withdrew.
Finally, 11,312 patients were included in the FAS, and 11,321 patients in the SS (Fig. 1 ). The detailed demographic and baseline characteristics of the patients are presented in ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin-II receptor blockers, BMI body mass index, BP blood pressure, CCBs calcium channel blockers, CHD chronic heart disease, DBP diastolic blood pressure, HF heart failure, SBP systolic blood pressure
Efficacy in Different Subgroups
The patients were grouped based on their age as \65 years, 65-\80 years, and C80 years. The mean BP-lowering efficacy of Val/Aml SPC was independent of age ( Fig. 3) . Another subgroup analysis based on baseline SBP levels (i.e., SBP \140, 140-159, 160-179, and C180 mmHg) showed significant reductions in MSSBP and MSDBP (P\0.0001) from baseline in all the baseline SBP groups after 8 weeks of treatment (Fig. 4) . Table 2 ). Only three serious AEs were reported during the study; none of them were suspected to be related to the treatment. The tolerability of Val/Aml SPC as evaluated by investigators and patients was quite similar; both evaluations were rated as 'very good' by 63.3% (n = 7,170) and 61.3% 
DISCUSSION
The present study is the first evidence-based, multicenter, observational real-world study that demonstrates the effectiveness and safety of Val/Aml SPC in reducing BP in a very large number of Chinese hypertensive patients. This study also showed that Val/Aml SPC was well tolerated with a good safety profile, even in patients aged 80 years and older (safety data not presented by age group). The prevalence rate of hypertension is on the rise in China, due to lack of awareness and treatment in addition to [8, 34] . In this study, as reported by the patients, more than 85% of patients took 80% or more of the Val/Aml SPC, which could be one of the reasons for improved efficacy. This reinforces the fact that SPC therapy could improve adherence, which is an important factor that influences BP-lowering efficacy of the drug [35] . Combination therapy has the potential for attenuation of certain drug class-specific AEs [2] . Val/Aml SPC was well tolerated in this study. There was a low incidence of AEs reported in each treatment phase, with three serious AEs occurring; none of them was suspected to be related to study treatment. A common AE of CCBs is peripheral edema which occurs due to arteriolar dilatation, causing intracapillary hypertension and fluid extravasation [36] . Despite the use of a CCB (i.e., Aml) in the treatment phase, the incidence of peripheral edema was low with the SPC treatment. This may be attributed to a short observational period, a different dose, or minimization of CCB-induced edema by the ARB (i.e., Val) [2] . Likewise, a randomized 
